| Bioactivity | Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research[1]. |
| Name | Bepranemab |
| CAS | 2244960-75-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Matthew E Barton, et al. Design of a patient- and investigator-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer’s disease: The TOGETHER Study, AH0003. Alzheimer's & Dementia. 31 December 2021. |